Alagebrium chloride is an advanced glycation end-product (AGE) inhibitor used to: increase endothelial cell (EC) proliferation, particularly on aortic matrix from obese and diabetic rats; reduce renal mass and hyperfiltration in diabetic RAGE/apoE double-knockout mice; further decrease glomerular collagen IV levels toward those observed in control mice; increase blood flow in obese (ZO) rats; reduce distal vascular resistance in diabetic (ZD) rats; decrease neointimal hyperplasia (NH) in trastut thickness as a function of local radius; and significantly increase TGF-β expression in the abdominal aorta (AAo) of Zucker lean (ZL) rats.